Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. PRGO
PRGO logo

PRGO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
10.525
Open
10.180
VWAP
10.21
Vol
3.74M
Mkt Cap
1.42B
Low
10.015
Amount
38.21M
EV/EBITDA(TTM)
6.96
Total Shares
137.65M
EV
4.53B
EV/OCF(TTM)
18.97
P/S(TTM)
0.33
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
Show More

Events Timeline

(ET)
2026-02-26
16:30:00
Nasdaq Lags Despite Nvidia's Earnings Beat and Strong Guidance
select
2026-02-26
12:20:00
Nasdaq Index Falls 1.63% as Market Confidence Wanes
select
2026-02-26
09:10:00
Sees FY26 Revenue Down 5.5% to 1.5%
select
2026-02-26
09:10:00
Perrigo Reports Q4 Revenue of $1.11B
select

News

Benzinga
8.5
17:03 PMBenzinga
Emerging Consolidation Wave in U.S. Markets
  • Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
  • Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
  • Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
  • Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
NASDAQ.COM
8.5
03-06NASDAQ.COM
Small Caps Rebound with Yields Up to 11%
  • Strong Small Cap Performance: Small caps have shown impressive performance in 2026, attracting investor interest due to their relatively cheap valuations despite risks of economic turbulence, which is expected to continue driving the market forward.
  • Washington Trust Bancorp Yield: Washington Trust Bancorp (WASH) offers a dividend yield of 6.6%, achieving a 27% earnings growth in 2025, with a price-to-earnings ratio of just 10 times, highlighting its competitiveness in the financial sector.
  • Diversified Energy Company Dynamics: Diversified Energy Company (DEC) attracts investors with an 8% dividend yield; although its growth potential is limited, it maintains stable cash flow and dividend payments through the acquisition of long-life assets.
  • HR Company Outlook: Insperity (NSP) provides an 11% dividend yield, facing challenges with declining profits, yet its revenue continues to grow, with potential for business transformation through a new platform.
PRnewswire
1.0
03-03PRnewswire
Perrigo CEO to Present at UBS Conference
  • Conference Schedule: Perrigo's CEO Patrick Lockwood-Taylor is set to present at the UBS Global Consumer and Retail Conference on March 11, 2026, at 11:00 AM EDT, highlighting the company's leadership in consumer health.
  • Webcast Access: Interested parties can access the conference webcast via Perrigo's official website, ensuring that investors and the public can stay updated on the company's latest developments and strategic direction.
  • Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience, focusing on high-quality health and wellness solutions primarily for North America and Europe, emphasizing accessibility in over-the-counter self-care products.
  • Business Model: Perrigo's unique business model leverages cash-generative private label offerings to fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, showcasing its competitive advantage in the market.
Benzinga
6.5
03-03Benzinga
Dividend Stocks Gain Favor Amid Market Turbulence
  • Investor Preference: During turbulent and uncertain market conditions, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
  • Analyst Ratings: Benzinga provides the latest analyst ratings for three high-yielding healthcare stocks, including Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc, assisting investors in making more informed decisions.
  • Market Data: Benzinga's analyst ratings page allows traders to sort through ratings based on analyst accuracy, offering a wealth of market data that enhances investor insights into stock performance.
  • Attractiveness of Dividend Stocks: High dividend stocks become particularly appealing in uncertain market environments as investors seek to hedge against risks posed by market volatility through stable dividend income.
NASDAQ.COM
2.0
02-26NASDAQ.COM
Perrigo (PRGO) Q4 2025 Earnings Call Transcript
seekingalpha
2.0
02-26seekingalpha
Perrigo Company Q4 2025 Earnings Call Insights
  • Market Share Gains: Perrigo achieved over $100 million in new distribution and competitive market share gains in 2025, with the CEO emphasizing that this progress reflects strong engagement with consumers and retailers, despite a generally soft market environment.
  • Stable Financial Performance: The company's 2025 GAAP results showed a 2% increase in operating income and a 7% rise in EPS to $2.75, aligning with revised guidance, even as core organic net sales declined by 2%.
  • Strategic Transformation Plan: Perrigo announced the introduction of new reporting segments in 2026, including Self-care, Specialty Care, and Infant Formula, to provide clearer performance insights, while also planning a global workforce reduction of approximately 7% over the next two years, with expected annualized pretax savings of $80 million to $100 million.
  • Cautious Future Outlook: Management anticipates 2026 to be a
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
Wall Street analysts forecast PRGO stock price to rise
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
18.00
Averages
20.33
High
23.00
Current: 0.000
sliders
Low
18.00
Averages
20.33
High
23.00
JPMorgan
Neutral
downgrade
$18 -> $15
AI Analysis
2026-02-27
Reason
JPMorgan
Price Target
$18 -> $15
AI Analysis
2026-02-27
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Perrigo to $15 from $18 and keeps a Neutral rating on the shares.
Canaccord
Susan Anderson
Buy
downgrade
$20 -> $17
2026-02-27
Reason
Canaccord
Susan Anderson
Price Target
$20 -> $17
2026-02-27
downgrade
Buy
Reason
Canaccord analyst Susan Anderson lowered the firm's price target on Perrigo to $17 from $20 and keeps a Buy rating on the shares. The firm said Management noted they ended 4Q25 and FY25 with share gains for both private label store brands and their key branded business, but saw softness in the infant nutrition business. It's been a challenging 2 years for the company primarily due to issues around the infant nutrition business. However, the rest of the business is performing well with distribution, contract, and share gains in a tough environment.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PRGO
Unlock Now

Valuation Metrics

The current forward P/E ratio for Perrigo Company PLC (PRGO.N) is 4.80, compared to its 5-year average forward P/E of 12.16. For a more detailed relative valuation and DCF analysis to assess Perrigo Company PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
12.16
Current PE
4.80
Overvalued PE
16.03
Undervalued PE
8.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
10.71
Current EV/EBITDA
7.35
Overvalued EV/EBITDA
12.53
Undervalued EV/EBITDA
8.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.98
Current PS
0.45
Overvalued PS
1.22
Undervalued PS
0.75

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

rerun right now to see if the list changes
Intellectia · 29 candidates
Price: $3.00 - $100.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 60One Day Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SIDU logo
SIDU
Sidus Space Inc
234.80M
DBGI logo
DBGI
Digital Brands Group Inc (Pre-Reincorporation)
68.45M
MED logo
MED
Medifast Inc
128.60M
AAP logo
AAP
Advance Auto Parts Inc
2.75B
CMBT logo
CMBT
CMB.TECH NV
3.30B
LSTA logo
LSTA
Lisata Therapeutics Inc
35.81M
best unvalued stock to buy
Intellectia · 43 candidates
Dividend Yield Ttm: >= 3Beta: LowRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 12P/B Ratio: <= 1.20P Fcf Ratio: <= 8.00
Ticker
Name
Market Cap$
top bottom
PRGO logo
PRGO
Perrigo Company PLC
2.05B
NGL logo
NGL
NGL Energy Partners LP
1.27B
ATNI logo
ATNI
ATN International Inc
350.00M
DOW logo
DOW
Dow Inc
20.19B
CTO logo
CTO
CTO Realty Growth Inc
587.23M
GEL logo
GEL
Genesis Energy LP
2.08B
best medical 3 stocks to buy under $20
Intellectia · 22 candidates
Market Cap: >= 500.00MPrice: <= $20.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
HLN logo
HLN
Haleon PLC
45.60B
KVUE logo
KVUE
Kenvue Inc
33.30B
VTRS logo
VTRS
Viatris Inc
15.03B
RDY logo
RDY
Dr Reddy's Laboratories Ltd
11.06B
BAX logo
BAX
Baxter International Inc
10.13B

Whales Holding PRGO

T
Thompson, Siegel & Walmsley LLC
Holding
PRGO
+4.66%
3M Return
Y
Yelin Lapidot Holdings Ltd.
Holding
PRGO
+3.33%
3M Return
B
BW Gestao de Investimentos Ltda.
Holding
PRGO
-0.75%
3M Return
S
Sound Income Strategies, LLC
Holding
PRGO
-6.41%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Perrigo Company PLC (PRGO) stock price today?

The current price of PRGO is 10.1 USD — it has decreased -1.85

What is Perrigo Company PLC (PRGO)'s business?

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

What is the price predicton of PRGO Stock?

Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is20.33 USD with a low forecast of 18.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Perrigo Company PLC (PRGO)'s revenue for the last quarter?

Perrigo Company PLC revenue for the last quarter amounts to 1.11B USD, decreased -2.52

What is Perrigo Company PLC (PRGO)'s earnings per share (EPS) for the last quarter?

Perrigo Company PLC. EPS for the last quarter amounts to -10.31 USD, increased 3121.88

How many employees does Perrigo Company PLC (PRGO). have?

Perrigo Company PLC (PRGO) has 8100 emplpoyees as of March 10 2026.

What is Perrigo Company PLC (PRGO) market cap?

Today PRGO has the market capitalization of 1.42B USD.